Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post by Saudi Embassy USA, adding:
“Honored that the Saudi Embassy USA posted this recognition of ImmunityBio efforts to bring Immunotherapy 2.0 as the next generation cancer care to their nation and embraced the concept of the power of NK and T cells to drive memory T cells.
Current fully enrolled studies across multiple tumor types including demonstrating that Anktiva increases lymphocytes, with data bases locked to be submitted for expanded and accelerated approval in the region, not unlike the multiple approvals USA FDA awarded Merck for Keytruda based on single arm trials- more details of this to come.
Randomized trials already in motion for BCG naive and first plus second line lung cancer at global sites. Now multiple new confirmatory indications designed to address the previously unrecognized disease that causes early mortality – called lymphopenia – – will be all opened in short order in the region.
From addressing sepsis to colon cancer to liver cancer and lymphopenia . Lymphopenia is a real disease and for the first time we have a way to address it. Remarkably the number one ranked cytokine ( now Anktiva) to cure cancer and stimulate lymphocytes was recognized as far back as 2007 by NCI and a consortium of scientists from NIH, FDA, AACR and AsH ..more to come.”
Quoting Saudi Embassy USA‘s post:
“Saudi-U.S. collaboration continues to drive breakthroughs in healthcare innovation. ImmunityBio regional expansion in the Kingdom is strengthening access to advanced cancer therapies and supporting physicians and health systems across the Middle East and North Africa.
These milestones reinforce Saudi Arabia’s growing role as a regional hub for medical innovation and patient care in line with Vision 2030.”
Other articles featuring Pat Soon-Shiong on OncoDaily.